ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1334

Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study

Andrea Delle Sedie1, Emanuele Calabresi1, Ilaria Romagnoli1, Linda Carli2 and Marta Mosca2, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), interstitial lung disease, Psoriatic arthritis, Spondylarthropathies, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence of about 10-60%) and the second cause of mortality (after cardiovascular diseases). Spondyloarthritides (SpA) are chronic arthritides that share with RA both a similar disease burden and similar therapeutical approaches. ILD evaluation is challenging, given the low sensitivity of X-ray and pulmonary function tests, and radiation linked to repetitive HRCT. Lung Ultrasound (LUS) has shown potential in the evaluation of ILD in autoimmune diseases. The aim of this study was to assess the prevalence of ILD in a cohort of SpA patients (pts) using LUS with respect to healthy controls (HC).

Methods: Consecutive SpA out-pts were examined by LUS, applying the definition for pleural line irregularity (PLI) recently provided by the OMERACT taskforce for LUS in systemic sclerosis (1). Seventy-one intercostal spaces were studied (14 in the anterior chest, 27 lateral and 30 posterior) in all the pts/HC using an Esaote MyLab25 Gold US machine with a linear 7.5-10 MHz probe. The scoring system by Pinal-Fernandez et al (2) was applied and a total pleural score was calculated. Each patient answered to Italian-validated PROs on respiratory function (Leicester and Saint-George), global health (SF-36) and dyspnea (mMRC scale). Clinical data on disease-duration, disease-onset, disease-activity (at the moment of the examination) and MTX/biologics treatment were collected from the medical records.

Results: Fifty-six SpA pts (35 psoriatic arthritis -PsA- and 21 ankylosing spondylitis -AS-) and 56 HC were studied. No significant differences were demonstrated between groups (SpA vs HC and PsA vs AS) for age, sex, BMI and smoking habits. The total pleural score was significantly higher in SpA pts than in HC (20.9+-11.8 vs 10.3+-7.7; p< 0.001). A positive correlation was found between total PLI score and PLI score from anterior, posterior and lateral chest. The posterior part of the chest showed a higher PLI score than the anterior and lateral one (with the latter resulting to be significantly lower than the posterior PLI score). Higher differences in the PLI average value between SpA pts and HC were registered for posterior and anterior part of the chest. No differences were found between PsA and AS (with a not statistically significant difference in the posterior PLI score, which was slightly higher in AS pts) (Tab.I).

Conclusion: LUS examination shows a higher amount of PLI in SpA with respect to HC. References: 1- Delle Sedie A et al. Ann Rheum Dis 2019;78(Suppl 2):A834 2- Pinal-Fernandez I et al. Clin Exp Rheumatol 2015;33(4 Suppl 91):S136-41


Disclosure: A. Delle Sedie, None; E. Calabresi, None; I. Romagnoli, None; L. Carli, None; M. Mosca, None.

To cite this abstract in AMA style:

Delle Sedie A, Calabresi E, Romagnoli I, Carli L, Mosca M. Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/does-interstitial-lung-disease-represent-a-real-comorbidity-in-spondyloarthritis-patients-results-from-an-ultrasound-monocentric-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-interstitial-lung-disease-represent-a-real-comorbidity-in-spondyloarthritis-patients-results-from-an-ultrasound-monocentric-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology